2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - 271-273
Treatment Considerations, Combination Therapy, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Measurable Residual Disease, CLL, Research, Clinical Research, Clinical Trials, Epidemiology, Study Population, Human, Adult
PAPER

816 Results of alliance A041702, a randomized phase III study of ibrutinib plus obinutuzumab versus response-guided ibrutinib plus venetoclax and obinutuzumab in untreated older patients with chronic lymphocytic leukemia (CLL)

Jennifer A. Woyach, MD, Jun Yin, PhD2, Jennifer R. Brown, MD, PhD3, Shira Dinner, MD4, Gerard Lozanski, MD5, Richard F. Little, MD6, Cecelia R Miller, PhD7, Vijay Damarla, MD8, Wei Ding, MD, PhD9, Sameer A. Parikh, MBBS10, Deborah Stephens, DO11, Brian Hill, MD, PhD12, Roberto Rodriguez, MD13, Kerry A. Rogers, MD14, Christopher David Fletcher, MD15, Steven Rousey, MD16, Farrukh T Awan, M.D.M.S.,M.B.A.17, Navin Anthony18, Lindsey Fitzgerald, MD19, Nancy L. Bartlett, MD20, Yazhini Vallatharasu21, Eileen Johnston, MD22, Jose Leis, MD, PhD23, Aminah Jatoi, MD24, Jennifer Le-Rademacher, PhD25, Gabriela Perez Burbano26, Amy S. Ruppert Stark, PhD27, Anna Wall28, Elie Dib, MD29, Harry P. Erba, MD30, Mark R. Litzow, MD31, Selina Luger, MD, FRCPC32, Richard M. Stone, MD33, Geoffrey L. Uy, MD34, Wendy Stock, MD35, John Byrd, MD36
1 The Ohio State University, Columbus, Ohio, United States
2 Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota, United States
3 Dana Farber Cancer Institute, Boston, Massachusetts, United States
4 Alliance Protocol Operations Office, Chicago, Illinois, United States
5 The Ohio State University, Columbus, Ohio, United States
6 National Cancer Institute, Bethesda, Maryland, United States
7 The Ohio State University, Columbus, Ohio, United States
8 Illinois CancerCare, Bloomington, IL, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 University of North Carolina, Chapel Hill, North Carolina, United States
12 Cleveland Clinic, Cleveland, Ohio, United States
13 Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
14 The Ohio State University, Columbus, Ohio, United States
15 University of Wisconsin, Madison, Wisconsin, United States
16 Metro Minnesota Community Oncology Consortium, St Louis Park, Minnesota, United States
17 University of Texas Southwestern Cancer Center, Dallas, Texas, United States
18 University of North Carolina Pardee Cancer Center, Hendersonville, North Carolina, United States
19 Huntsman Cancer Center, University of Utah, Salt Lake City, Utah, United States
20 Washington University School of Medicine, St Louis, Missouri, United States
21 Froedert-Thedacare, Wisconsin NCI Community NCORP, Appleton, Wisconsin, United States
22 Swedish Cancer Institute, Edmonds, Washington, United States
23 Mayo Clinic, Phoenix, Arizona, United States
24 Mayo Clinic, Rochester, Minnesota, United States
25 Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota, United States
26 Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota, United States
27 Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota, United States
28 Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota, United States
29 Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor, Michigan, United States
30 Duke University, Durham, North Carolina, United States
31 Mayo Clinic, Rochester, Minnesota, United States
32 University of Pennsylvania, Philadelphia, Pennsylvania, United States
33 Dana Farber Cancer Institute, Boston, Massachusetts, United States
34 Washington University School of Medicine, St Louis, Missouri, United States
35 University of Chicago, Chicago, Illinois, United States
36 University of Pittsburgh and UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Background

Covalent Bruton’s tyrosine kinase inhibitors (cBTKi) such as ibrutinib +/- the anti-CD20 antibody obinutuzumab (IO) are standard frontline treatments for older adults with CLL. BTKi alone do not often lead to complete response (CR) or undetectable minimal residual disease (uMRD), thus are given indefinitely. IO plus venetoclax (IVO) can induce uMRD CRs which allows successful discontinuation, but outcomes in an older patient (pt) population are not well defined. A041702 (NCT03737981) is a multicenter, randomized phase 3 clinical trial designed to evaluate whether the triplet regimen of IVO with response-guided discontinuation is superior to a standard continuous regimen of IO for older adults with treatment-naïve CLL. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS) and bone marrow MRD-CR rates, MRD rates, and depth of response at cycle 15 day 1.

Patients and Methods

Eligible pts were initially age ≥70 years, subsequently amended to ≥65, and had CrCl > 40 mL/min, bilirubin < 1.5 x ULN, and no other life-limiting intercurrent illness. Pts were stratified based on Rai stage and presence or absence of del17p13.1 by central fluorescence in situ hybridization (FISH), and were randomized 1:1 to IO or IVO. With 431 evaluable pts, the trial had 90% power to detect a progression free survival (PFS) hazard ratio (HR) of 0.55 using a one-sided log-rank test with type I error rate of 2.5%.

IO was given in standard fashion with O given during cycles 1-6.  In the IVO arm V was added at cycle 3 day 1 and continued until cycle 14 day 28. After 14 cycles, patients underwent response evaluation. Patients in the IVO arm with uMRD and CR discontinued I; all others continued I until progression or unacceptable toxicity. 

On July 15, 2022, the Alliance Data and Safety Monitoring Board declared futility based on the pre-specified boundary where superiority for IVO could not be met. Because most patients had completed venetoclax, the trial was allowed to continue without modification, although patients were informed of the negative results. Given the substantial impact of COVID-19–related mortality on early outcomes, this analysis was conducted using more mature follow-up data.  Data were locked for this analysis November 17, 2025.

 Results

Between February 15, 2019 and August 9, 2022, 465 pts were randomized (IO:232, IVO:233). Median age was 74 years, 32% of pts were female, 13% had del17p13, and 52% were IGHV unmutated.  Complex karyotype, defined as 3 or more chromosomal abnormalities, was observed in 21% of IO and 31% of IVO patients. 

With median follow-up of 52.9 months, PFS was not significantly longer for IVO than IO (hazard ratio (HR) = 0.89; 95% confidence interval (CI): 0.64-1.24, one-sided p-value = 0.2414).  Median PFS was not reached for the IVO arm and was 70.1 months for IO.  Four-year PFS estimates were 72% for IO (95% CI: 66-79%) and 69% for IVO (95% CI: 62-75%).  On univariable analysis, male sex, del17p, and MYC abnormalities by FISH were all associated with shorter PFS.  Using multivariable modeling, male sex and presence of del17p by FISH were independently associated with shorter PFS.

At the time of this analysis, 109 patients had died, with no significant difference in OS between the two treatment arms (HR 0.98 for IVO (95% CI: 0.67-1.43), p=0.9087).  Four-year OS estimates were 80% for IO (95% CI: 75-86%) and 76% for IVO (95% CI: 71-82%).  Death related to COVID19 occurred in 19 patients on IO and 27 on IVO. 

Among the 342 pts (171 on IO and 171 on IVO) with evaluable bone marrow MRD at cycle 15, uMRD was more frequent with IVO than IO (88.3% vs 28.7%, p < 0.001), as was uMRD with CR (57.3% vs 12.9%, p < 0.001). Peripheral blood MRD was also performed in 332 pts and the results were concordant with the bone marrow evaluation 86% of the time (kappa = 0.715).

Conclusions

A041702 demonstrates that PFS for IVO is not superior to IO in older, treatment-naïve patients with CLL.  COVID19 related mortality was substantial in both arms, with more COVID19 related deaths observed in the IVO arm.  However, treatment with IVO achieved high rates of uMRD and uMRD CR.  These results demonstrate that both regimens can result in durable disease control.  Further follow-up will help elucidate if there are subgroups that may benefit from IVO despite increased toxicity.

Support: U10CA180821, U10CA180882, U24CA196171;
https://acknowledgments.alliancefound.org

Jennifer A. Woyach, MD: Johnson & Johnson - Honoraria; Merck - Honoraria; AbbVie - Honoraria; BeOne - Honoraria; AstraZeneca - Honoraria; Genentech - Honoraria; Loxo@Lilly - Honoraria; Newave - Honoraria; Loxo@Lilly - Research Funding; Merck - Research Funding; Newave - Research Funding; BeOne - Research Funding; AbbVie - Research Funding; Johnson & Johnson - Research Funding; BeOne - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Newave - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Loxo@Lilly - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony)